Authors : Sitbon O1Cottin V2Canuet M3Clerson P4Gressin V5Perchenet L5Bertoletti L6,7Bouvaist H8Picard F9Prévot G10Bergot E11Simonneau G12.


Initial combination therapy plays a central role in managing pulmonary arterial hypertension (PAH) [1–4]. Patients with low- or intermediate-risk of 1-year mortality at diagnosis should be treated with initial combinaton therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase type-5 inhibitor (PDE5i) [2–4]. Benefits of initial therapy with the ERA ambrisentan and PDE5i tadalafil were demonstrated in AMBITION [1]; prospective evidence for other treatment combinations within these drug classes is needed.


Suscribe to our newsletter